Related Experiment Videos

Novel receptor-targeted fluorescent contrast agents for in vivo tumor imaging

S Achilefu1, R B Dorshow, J E Bugaj

  • 1Discovery Research, Mallinckrodt Inc., St. Louis, Missouri 63042, USA. Samuel.achilefu@mkg.com

Investigative Radiology
|August 18, 2000
PubMed
Abstract

Insights

A novel fluorescent dye linked to a peptide effectively targets and highlights tumors in optical imaging. This receptor-specific contrast agent shows promise for improved cancer diagnosis and patient management.

Area of Science:

  • Biomedical Optics
  • Molecular Imaging
  • Cancer Diagnostics

Background:

  • Optical imaging offers a non-invasive method for tumor detection.
  • Targeted contrast agents are crucial for enhancing image sensitivity and specificity.
  • Developing receptor-specific agents improves tumor visualization.

Purpose of the Study:

  • To assess the efficacy of a novel small-peptide-near-infrared dye conjugate.
  • To evaluate its capability for tumor detection using optical imaging.
  • To determine if receptor specificity enhances tumor targeting.

Main Methods:

  • Synthesis of a near-infrared dye-peptide conjugate (cytate).
  • Evaluation in a rat tumor model (CA20948) expressing specific peptide receptors.
  • Utilized a continuous-wave optical imaging system with NIR laser and CCD camera.

Main Results:

  • Non-specific dyes (ICG, cypate) showed negligible tumor retention.
  • The receptor-specific conjugate (cytate) demonstrated significant retention in the target tumor.
  • Achieved an excellent tumor-to-normal-tissue ratio in optical imaging.

Conclusions:

  • Demonstrated successful optical tumor detection using a receptor-targeted fluorescent contrast agent.
  • This approach represents a novel strategy for cancer diagnosis.
  • Highlights potential for improved patient management through enhanced imaging.

Related Concept Videos